Status:
TERMINATED
Longitudinal Evaluation and Real-world Evidence of NT201
Lead Sponsor:
Merz North America, Inc.
Conditions:
Glabellar Frown Lines and Canthal Lines and/or Horizontal Forehead Lines in the Upper Face
Eligibility:
All Genders
18+ years
Brief Summary
This study is to collect long-term real-world evidence data from clinics in several countries in order to obtain an improved understanding of the safety and effectiveness of incobotulinumtoxinA in bot...
Eligibility Criteria
Inclusion
- 18 years of age or older.
- Planning treatment with incobotulinumtoxinA.
Exclusion
- Any contraindication to treatment with incobotulinumtoxinA or any other neurotoxins.
- Currently pregnant, breastfeeding, or intending to become pregnant during study participation.
- Known hypersensitivity to incobotulinumtoxinA or any of its formulation ingredients.
- Any infection and/or inflammation at the planned injection points.
- Previous treatment with any botulinum toxin products for any aesthetic or therapeutic indications.
Key Trial Info
Start Date :
February 10 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 18 2023
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT05222607
Start Date
February 10 2023
End Date
May 18 2023
Last Update
June 7 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
SkinDC
Arlington, Virginia, United States, 22209